Seplife Oligonucleotides Solid Phase Synthesis Pharma Grade API is a chemically synthesized single-stranded therapeutic oligonucleotide released under current good manufacturing practice for use as an active pharmaceutical ingredient in tablets, capsules, granules, and injectable dosage forms. The route exploits sequential solid-phase phosphoramidite coupling on a solid support, typically proceeding from the 3′ terminus to the 5′ terminus, and is operated under 21 CFR 210/211 and ICH Q7. Two release grades are available: an oral-grade dry powder intended for solid oral dosage forms and an injectable-grade powder or concentrate characterized by reduced endotoxin, bioburden, and subvisible-particulate controls. The API is a polyanionic, hygroscopic substance with a molecular mass typically in the range of 5,000–12,000 g/mol for 18–30 nucleotide sequences, depending on backbone chemistry and sugar modifications. Tablet, capsule, and granule applications generally use the oral-grade powder, whereas injectable products use the injectable-grade powder or pre-formulated concentrate.

At incoming receipt, the powder should be held at −20 °C ± 5 °C in sealed double polyethylene bags inside an aluminum foil overwrap when storage exceeds 30 days; for short-term processing up to 5 days, controlled room temperature at ≤25 °C and ≤35% relative humidity has been used. Re-equilibration to ambient temperature before opening is required to prevent surface condensation, because moisture uptake above 5.0% w/w increases particle cohesion and can reduce die-filling consistency during capsule and tablet manufacture.

What Distinguishes Solid-Phase Synthesis for Injectable Oligonucleotide APIs?

Each synthesis cycle comprises 3′-terminal deprotection, trityl removal with dichloroacetic acid or trichloroacetic acid in toluene or acetonitrile, followed by phosphoramidite activation, coupling, capping, and oxidation or sulfurization. The coupling step uses protected 2′-deoxy, 2′-O-methyl, or locked nucleic acid phosphoramidites at 0.10–0.20 mol/L in anhydrous acetonitrile. Coupling yields are monitored by trityl cation absorbance at 495–498 nm; a per-cycle coupling efficiency of 0.995 or greater is targeted for injectable-grade synthesis. For a 20-nucleotide sequence, 0.995 per-cycle efficiency corresponds to a pre-purification full-length fraction of approximately 0.905, while a 30-nucleotide sequence at the same efficiency corresponds to approximately 0.860. This arithmetic explains the direct relationship between chain length, N–1 deletion burden, and purification mass recovery.

The solid support is controlled-pore glass or cross-linked polystyrene with a long-chain alkylamine linker; loading densities of 40–100 µmol/g are used, with the lower-loading domain selected for longer sequences to reduce steric crowding and improve coupling kinetics. For phosphorothioate-containing sequences, oxidation is replaced by sulfurization using 3H-1,2-benzodithiol-3-one or phenylacetyl disulfide; incomplete sulfurization produces phosphodiester variants that are resolved by ion-pair reversed-phase high-performance liquid chromatography. Sulfurization efficiency is monitored by mass spectrometry, and the phosphodiester content is controlled to ≤1.0% of total sequence variants for injectable-grade material.

Crude cleavage and deprotection with ammonium hydroxide or methylamine under controlled time and temperature liberates the oligonucleotide from the support and removes nucleobase and phosphate protecting groups. The purification train for injectable-grade material uses two orthogonal chromatographic steps: an anion-exchange capture step with a quaternary ammonium strong-anion-exchange resin at conductivity 5–30 mS/cm, followed by ion-pair reversed-phase high-performance liquid chromatography with a C18 column and triethylammonium acetate/acetonitrile mobile phase. Final desalting and concentration are performed by tangential flow filtration using a 1–3 kDa regenerated cellulose or polyethersulfone membrane. The resulting peak fraction is controlled to ≤0.5 EU/mg bacterial endotoxin and ≤10 CFU/g bioburden before sterile filtration in the downstream drug-product process.

Production-scale solid-phase synthesizers are operated with fixed-bed columns of 0.5–5 L bed volume. Bed swelling and channeling are common failure modes when the resin is not slurried under vacuum before loading; a packed-bed integrity test is performed by measuring backpressure at a defined mobile-phase flow rate. Coupling reagent delivery is controlled by positive-displacement pumps with calibrated flow paths; failure sequences accumulate more rapidly at the 5′ end when flow distribution is uneven. Batch records therefore include time-series trityl release data, and any cycle with coupling efficiency below 0.990 triggers re-coupling or linear failure-sequence review.

The synthetic route does not introduce host-cell DNA, host-cell protein, or animal-derived components, but it creates a characteristic impurity profile dominated by N–1 deletion sequences, shortmers, and oxidation-related phosphodiester variants. The specification therefore requires ion-pair reversed-phase HPLC purity of not less than 90.0% and the sum of N–1 deletion products of not more than 5.0% for oral-grade material, with tighter limits applied to injectable-grade lots. Mass confirmation is performed by electrospray ionization time-of-flight mass spectrometry; the observed molecular mass must agree with the theoretical sequence mass within ±1.0 Da for a 20-mer. Published data for this specific configuration is limited; therefore, any limit not fixed by this document should be confirmed against the batch certificate of analysis.

Residual Solvent, Water, and Elemental Impurity Control in Tablet and Capsule Manufacturing

Solid oral dosage forms require a dry, flowable API. Lyophilized solid-phase API is usually an amorphous, low-bulk-density powder with a bulk density of 0.05–0.25 g/mL, a tap density of 0.10–0.45 g/mL, and a Carr compressibility index above 30, indicating cohesive powder flow. Dry granulation by roller compaction or slugging is preferred over aqueous wet granulation because the charged internucleotide linkage is subject to hydrolytic cleavage at elevated temperature and pH extremes; the drying step in aqueous granulation can increase related substances and reduce assay. Water content is determined by Karl Fischer titration because the API can retain water in two states: surface moisture and bound hydration water. The oral-grade specification is set at ≤10.0% w/w to permit processing in non-condensing environments, while the injectable-grade specification is set at ≤5.0% w/w to minimize hydrolysis during storage and to reduce variability in final drug product reconstitution.

Residual solvent clearance in injection-grade material is confirmed by headspace gas chromatography with flame ionization detection, not by loss on drying. Acetonitrile is controlled to ≤410 ppm consistent with ICH Q3C class 2 guidance. For capsule filling, the API is premixed with mannitol, microcrystalline cellulose, and croscarmellose sodium by geometric dilution to improve content uniformity. Low-dose formulations at 0.5–10 mg per unit must meet USP <905> uniformity of dosage units; powder blend uniformity is controlled by sampling with a sample thief at 10–20 locations and analyzing API concentration by UV absorbance at 260 nm after extraction. If relative humidity exceeds 60%, pre-drying in a vacuum oven at 25–35 °C for 4–12 h should be applied immediately before blending; pre-dried material has been observed to reabsorb moisture within 30–60 min in an uncontrolled environment, causing weight variation during high-speed capsule filling. Subsequent blending and encapsulation should therefore be conducted under ≤25% relative humidity.

Granule manufacture via dry granulation uses a roller compactor with 0.8–1.2 mm screen milling; friability and particle-size distribution are adjusted to produce granules passing 20 mesh and retained on 60 mesh for capsule and tablet feed. Compression at 5–10 kN for tablet matrices may be possible when the API is diluted; however, plastic deformation of the amorphous API under load can increase ejection force and should be evaluated with an instrumented tablet press. The API is not a direct-compression material; its low bulk density and high static charge require formulation strategies such as roller compaction or slugging. The sodium salt form is supplied to reduce counterion variability, with residual sodium controlled by ion chromatography.

When Direct Injection Formulation Requires Sterility Assurance Without Terminal Heat

Injectable formulations of solid-phase oligonucleotide APIs are generally not autoclaved because the phosphorothioate or phosphodiester backbone can degrade under saturated-steam conditions at 121 °C, and terminal gamma irradiation can generate free radicals that alter base integrity. Sterility assurance therefore depends on aseptic processing and membrane filtration. The drug product is typically dissolved in Water for Injection at 0.5–20 mg/mL, adjusted to pH 7.0–7.5, and filtered through a 0.22 µm membrane filter rated by ASTM F838-20 for bacterial retention. Filter integrity is confirmed by water intrusion or bubble-point test before and after filtration. Final containers are filled under ISO 14644-1 Grade A conditions and require compliance with USP <71> sterility, USP <85> endotoxin, and USP <788> subvisible particulate matter.

Osmolality is adjusted to 280–320 mOsm/kg with sodium chloride or mannitol; pH shift and aggregation should be checked by dynamic light scattering and size-exclusion chromatography. The API is compatible with phosphate-buffered saline at pH 7.4, but divalent cations can induce aggregation, so calcium- and magnesium-containing diluents should be avoided unless preformulation data support compatibility. Terminal lyophilization of the drug product, when required, uses a cycle with freezing at −40 °C to −50 °C, primary drying at −20 °C to −10 °C at 0.1–0.2 mbar, and secondary drying at 20–25 °C for 8–16 h; cake appearance and reconstitution time are monitored by visual inspection and turbidity measurement. Subvisible particle counts for the reconstituted injectable solution must comply with USP <788> Method 1 light obscuration: not more than 6,000 particles ≥10 µm and not more than 600 particles ≥25 µm per container after product-specific dilution. The API itself is not tested as a final container; the test is performed on the finished injection.

Direct Solid-Phase API Versus Solution-Phase and Biologically Derived Nucleic Acid Reagents

The principal difference between Seplife solid-phase API and solution-phase or fermentation-derived nucleic acid products is the control of sequence and modification pattern. Solid-phase coupling permits site-specific introduction of 2′-O-methyl, 2′-fluoro, locked nucleic acid, and phosphorothioate moieties at defined positions, while biologically derived RNA or DNA has heterogeneous post-transcriptional modifications and host-cell impurities. Compared with solution-phase oligonucleotide synthesis, solid-phase chemistry avoids repeated isolation and precipitation after each coupling, but scale is constrained by the packed-bed volume and ligand density of the support; synthesis columns with 0.5–5 L bed volumes are typical for production campaigns. This yields batch sizes that are generally lower than those of conventional small-molecule APIs, and chromatographic yield is highly dependent on chain length and failure-sequence accumulation.

In regulatory terms, the API specification therefore includes sequence identity by mass spectrometry, duplex melting temperature, and endotoxin control, rather than only assay and related substances. Oral and injectable grades differ primarily in residual water, bioburden, endotoxin, and airtight packaging requirements; the chemical entity and impurity profile remain the same. The solid-phase route is not appropriate for sequences above approximately 50–60 nucleotides at current coupling efficiencies because the pre-purification full-length fraction falls below 0.20, making purification mass recovery economically impractical. This boundary is an operational limitation, not a formulation incompatibility. The API should be handled as a potent polyanionic active pharmaceutical ingredient with dedicated weighing, blending, and cleaning procedures to prevent cross-contamination; cleaning validation follows 21 CFR 211.67 and should demonstrate residues below the acceptable daily exposure for the specific sequence.